Drug Development | Novartis

Novartis at ASCO and EHA 2022

Driven by our passion for patients and grounded in our industry-leading pipeline of 45+ different compounds across 70+ development programs, Novartis is rapidly advancing novel cancer treatment approaches in areas of great medical need.

CancerDisease AwarenessDrug DevelopmentOncology
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19

Basel, January 10, 2022 — Novartis and Molecular Partners today announced that Part A of the EMPATHY clinical trial1 that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo to treat COVID-19, met the primary endpoint of viral load reduction over eight days. The two secondary endpoints also showed…

Reimagine MedicineInnovationDrug Development
En 2020, Novartis a enregistré une croissance de son chiffre d’affaires et de sa marge; il a continué de faire progresser sa prochaine vague de médicaments

Bâle, le 26 janvier 2021 - En commentant les résultats, Vas Narasimhan, CEO de Novartis, a déclaré: «En dépit des défis posés par le Covid-19, Novartis a réalisé une excellente performance en 2020 dans toutes ses priorités stratégiques. Sur le plan opérationnel, nous avons augmenté notre chiffre d’affaires et continué d’améliorer nos marges…

Reimagine MedicineFuture of HealthcareDrug DevelopmentAccess to Healthcare
Novartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben

Basel, 26. Januar 2021 — Die Ergebnisse 2020 kommentierte Vas Narasimhan, CEO von Novartis: «Novartis hat 2020 trotz der Herausforderungen durch COVID-19 bei allen strategischen Prioritäten solide Ergebnisse erzielt. Operativ konnten wir den Umsatz steigern und die operativen Kerngewinnmargen bei Innovative Medicines verbessern. Wir haben unsere…

Reimagine MedicineFuture of HealthcareDrug DevelopmentAccess to Healthcare
Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.

Basel, January 26, 2021 - commenting on 2020 results, Vas Narasimhan, CEO of Novartis, said: “Novartis delivered a solid performance in 2020 across our strategic priorities, despite the challenges of COVID-19. Operationally, we grew sales and continued to improve core operating margins for Innovative Medicines. We advanced our next wave of…

Reimagine MedicineFuture of HealthcareDrug DevelopmentAccess to Healthcare
Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)

Ad hoc announcement pursuant to Art. 53 LR

Reimagine MedicineDrug DevelopmentAd Hoc
Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms

Basel, December 2, 2021 — Novartis today holds an investor event to provide a comprehensive overview of the company’s progress in advancing its industry-leading R&D engine.

InnovationFuture of HealthcareDrug Development
Discovery

The art of drug design in a technological age

Novartis is collaborating with Microsoft to apply machine learning to medicinal chemistry — part of an effort to leverage AI to bring treatments to patients more efficiently.

Biomedical ResearchData ScienceDrug DevelopmentDrug DiscoveryEmerging Technology
Access to Healthcare

To make a difference, start with patients

John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.

Drug DevelopmentInnovationWorking at Novartis
Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program

Basel, September 23, 2020 – Novartis Gene Therapies recently received feedback from the US Food and Drug Administration (FDA) following their review of data from the STRONG study of the intrathecal (IT) formulation of AVXS-101 in older patients with spinal muscular atrophy (SMA). The FDA has acknowledged the potential of AVXS-101 IT in this…

Drug DevelopmentClinical TrialsAd Hoc
Novartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)

Basel, October 9, 2020 — Novartis today announced that the European Medicines Agency (EMA) has granted PRIME designation for iptacopan (LNP023) in C3 glomerulopathy (C3G). PRIME is a program launched by the EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary program is based on enhanced…

Reimagine MedicineDrug Development
En 2020, Novartis a enregistré une croissance de son chiffre d’affaires et de sa marge; il a continué de faire progresser sa prochaine vague de médicaments

Bâle, le 26 janvier 2021 - En commentant les résultats, Vas Narasimhan, CEO de Novartis, a déclaré: «En dépit des défis posés par le Covid-19, Novartis a réalisé une excellente performance en 2020 dans toutes ses priorités stratégiques. Sur le plan opérationnel, nous avons augmenté notre chiffre d’affaires et continué d’améliorer nos marges…

Reimagine MedicineFuture of HealthcareDrug DevelopmentAd HocAccess to Healthcare